TY - JOUR
T1 - The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH)
AU - Kakazu, Eiji
AU - Kondo, Yasuteru
AU - Ninomiya, Masashi
AU - Kimura, Osamu
AU - Nagasaki, Futoshi
AU - Ueno, Yoshiyuki
AU - Shimosegawa, Tooru
N1 - Funding Information:
Acknowledgements This work was supported by Grant-in-Aid for Young Scientists (B), no. 23790762, from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and grants from Ministry of Health, Labor, and Welfare of Japan. We thank Chikako Sato for excellent technical assistance.
PY - 2013/6
Y1 - 2013/6
N2 - Background and aims: The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand, piglitazone, enhances the degradation of branched-chain amino acids (BCAAs) in adipose tissue. However, it remains unknown whether pioglitazone influences the plasma amino acids (AA) profile in patients with nonalcoholic steatohepatitis (NASH). Thus, we investigated the relation between the therapeutic effect and the AA profile in NASH patients with a prospective study. Methods: We randomized 25 histologically proven NASH patients to diet treatment only or diet treatment plus pioglitazone (15 mg/day), and investigated the biological data for 24 months. We measured the concentrations of AAs and compared them between the beginning and the end of the study. Results: Compared with the diet only group, pioglitazone therapy was associated with an increase in body weight (mean change -1.03 vs. +3.8 kg; p = 0.027) and subcutaneous fat (-3.7 vs. +45.7 cm2; p = 0.056), and decreased ALT levels (-0.6 vs. -38.4 IU/L; p = 0.029) and HbA1c (0.33 vs. -0.29 %; p = 0.016). Regarding the AA profile, l-isoleucine, l-leucine, l-histidine, and l-lysine were significantly reduced in patients treated with pioglitazone. Furthermore, l-leucine was significantly reduced compared with those in the diet only group (mean change -34.8 vs. +4.12 nmol/mL; p = 0.032). Interestingly, there was a significant correlation between the changes in BCAAs, especially l-leucine, and those in ALT regardless of treatment with pioglitazone. Conclusions: Pioglitazone therapy in NASH subjects significantly reduced the plasma BCAA level and the degradation was closely related to the improvement of the ALT levels. These results suggest that pioglitazone improves insulin resistance and BCAA metabolism in NASH patients.
AB - Background and aims: The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand, piglitazone, enhances the degradation of branched-chain amino acids (BCAAs) in adipose tissue. However, it remains unknown whether pioglitazone influences the plasma amino acids (AA) profile in patients with nonalcoholic steatohepatitis (NASH). Thus, we investigated the relation between the therapeutic effect and the AA profile in NASH patients with a prospective study. Methods: We randomized 25 histologically proven NASH patients to diet treatment only or diet treatment plus pioglitazone (15 mg/day), and investigated the biological data for 24 months. We measured the concentrations of AAs and compared them between the beginning and the end of the study. Results: Compared with the diet only group, pioglitazone therapy was associated with an increase in body weight (mean change -1.03 vs. +3.8 kg; p = 0.027) and subcutaneous fat (-3.7 vs. +45.7 cm2; p = 0.056), and decreased ALT levels (-0.6 vs. -38.4 IU/L; p = 0.029) and HbA1c (0.33 vs. -0.29 %; p = 0.016). Regarding the AA profile, l-isoleucine, l-leucine, l-histidine, and l-lysine were significantly reduced in patients treated with pioglitazone. Furthermore, l-leucine was significantly reduced compared with those in the diet only group (mean change -34.8 vs. +4.12 nmol/mL; p = 0.032). Interestingly, there was a significant correlation between the changes in BCAAs, especially l-leucine, and those in ALT regardless of treatment with pioglitazone. Conclusions: Pioglitazone therapy in NASH subjects significantly reduced the plasma BCAA level and the degradation was closely related to the improvement of the ALT levels. These results suggest that pioglitazone improves insulin resistance and BCAA metabolism in NASH patients.
KW - Branched-chain amino acids
KW - Nonalcoholic steatohepatitis
KW - PPAR-γ
KW - Pioglitazone
UR - http://www.scopus.com/inward/record.url?scp=84879844053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879844053&partnerID=8YFLogxK
U2 - 10.1007/s12072-012-9395-y
DO - 10.1007/s12072-012-9395-y
M3 - Article
AN - SCOPUS:84879844053
VL - 7
SP - 577
EP - 585
JO - Hepatology International
JF - Hepatology International
SN - 1936-0533
IS - 2
ER -